BIOPOR Bioporto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

May 5, 2021

Announcement no. 10

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

After having led BioPorto as CEO for almost 8 years, BioPorto’s Chief Executive Officer, is resigning his position as CEO of the Company. Peter will continue to support the Company until end of January 2022, and will retain his position as CEO until his successor has been found.

Peter Mørch Eriksen says: “It is, and has been, a privilege to be CEO of BioPorto, and I look forward to continue to support the Company’s ongoing projects, including the clinical studies and expected submission this summer of a De Novo application to the FDA for pediatric use of The NGAL Test™. Considering the important milestones ahead for BioPorto, I find this to be the right time to find my successor who can lead the Company into its next phase.”

Thomas Magnussen, Chairman of the Board of Directors, says: “I wish to thank Peter for his tremendous efforts for the Company over many years. I and the rest of the organization look forward to continue working with Peter over the coming months, as we proceed to identify and appoint his successor and further advance the ongoing transition of the Company to the North American market.”

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
05/05/2021

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voks...

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off 31. marts, 2026Meddelelse no. 6 BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off KØBENHAVN, DANMARK, 31. marts, 2026 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH: BIOPOR) meddelte i dag, at de formelt har indsendt deres FDA Pre-submission pakke til den amerikanske Food and Drug Administration (FDA). Dette markerer en vigtig regulatorisk milepæl for Selskabet ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submissio...

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary an...

March 31, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S 26. marts 2026Selskabsmeddelelse nr. 5 Indkaldelse til ordinær generalforsamling i BioPorto A/S Bestyrelsen indkalder hermed til ordinær generalforsamling i BioPorto A/S ("BioPorto" eller "Selskabet"), som afholdes: 24. april 2026 kl. 15.00på Selskabets adresseTuborg Havnevej 15, st., 2900 Hellerup, Danmark DAGSORDEN: PUNKT 1 - BERETNING OM SELSKABETS VIRKSOMHED I DET FORLØBNE ÅR Bestyrelsen foreslår, at bestyrelsens beretning om Selskabets virksomhed i det forløbne år tages til efterretning. PUNKT 2 – FREMLÆGGELSE AF ÅRSRAPP...

March 26, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Notice convening the Annual General Meeting in BioPorto A/S

Notice convening the Annual General Meeting in BioPorto A/S 26 March 2026Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 24 April 2026 at 3.00 p.m. (CEST)at the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the past year be noted. ITEM 2 – PRESENT...

March 26, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto annoncerer Årsrapporten for 2025

BioPorto annoncerer Årsrapporten for 2025 26. marts 2026Meddelelse nr. 04                                                                                                                                                                                                BioPorto annoncerer årsrapporten for 2025 København, Danmark, 26. marts 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller selskab) (CPH:BIOPOR) offentliggjorde i dag de finansielle resultater for året 2025. De finansielle resultater for 2025 bekræfter de foreløbige, ureviderede finansielle tal for 202...

March 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch